Homocysitaconate controls inflammation through reshaping methionine metabolism and N-homocysteinylation.

Summary

This mechanistic study identifies homocysitaconate, a metabolite produced by AHCY-mediated adduction of homocysteine and itaconate, as a potent anti-inflammatory mediator. It inhibits MARS, reshapes methionine metabolism to curb N-homocysteinylation, promotes NLRP3 ubiquitination, and shows therapeutic efficacy in sepsis models.

Key Findings

• Homocysitaconate levels increased 152-fold during inflammation and exhibited anti-inflammatory activity.
• Mechanistically, homocysitaconate bound MARS at D312, inhibiting its function and reshaping methionine metabolism to brake N-homocysteinylation.
• The metabolite facilitated NLRP3 ubiquitination and showed therapeutic efficacy in sepsis, diet-induced inflammation, and colitis models.
• Endogenous synthesis could be boosted via NAD-linked pathways (as indicated), suggesting druggability.

Clinical Implications

Although preclinical, augmenting homocysitaconate or modulating AHCY/MARS could represent a new anti-inflammatory strategy in sepsis, potentially complementing antibiotics and organ support.

Limitations

• Preclinical models; human pharmacokinetics, safety, and optimal dosing remain unknown.
• Abstract truncation leaves details on NAD-linked augmentation and off-target effects unclear.

Future Directions

Define pharmacology, safety, and delivery strategies for homocysitaconate augmentation; validate immunometabolic signatures and target engagement in human sepsis; explore AHCY/MARS modulators.